Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The PANoptosome: A Deadly Protein Complex Driving Pyroptosis, Apoptosis, and Necroptosis (PANoptosis)

Frontiers in Cellular and Infection Microbiology(2020)10.3389/fcimb.2020.00238Source: DataRank Database

The PANoptosome: A Deadly Protein Complex Driving Pyroptosis, Apoptosis, and Necroptosis (PANoptosis) is a research paper published in Frontiers in Cellular and Infection Microbiology (2020). On theSindex it has a DataRank of 0. It has been cited 535 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access535 citations

Download PDF

Cite:

Linked data & code

gen doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 15.58)OA: goldTopics (27)Linked Datasets (18)DataCite Reuse (18)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

R. K. Subbarao Malireddi ORCID,Thirumala‐Devi Kanneganti ORCID,Parimal Samir ORCID

Live enrichment

PubMed:32582562 PMC:PMC7283380 OpenAlex:https://openalex.org/W3034103545

NIAID NIH HHS

Grant: R01 AI124346

NCI NIH HHS

Grant: R01 CA163507

NIAID NIH HHS

Grant: R37 AI101935

NIAMS NIH HHS

Grant: R01 AR056296

NIAID NIH HHS

Grant: R01 AI101935

American Lebanese Syrian Associated Charities

National Institutes of Health

FWCI

15.58

Citation Percentile

1.0%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.frontiersin.org/articles/10.3389/fcimb.2020.00238/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fcimb.2020.00238/pdf

publisherhttps://www.frontiersin.org/article/10.3389/fcimb.2020.00238/full

journalhttps://doi.org/10.3389/fcimb.2020.00238

repositoryhttps://pubmed.ncbi.nlm.nih.gov/32582562

Fields of Study

Inflammasome and immune disordersinterferon and immune responsesRNA modifications and cancer

MeSH Terms

PyroptosisNecroptosisHumansPhylogenyApoptosis

Keywords

PyroptosisNecroptosisProgrammed cell deathBiologyCell biologyProinflammatory cytokineComputational biologyApoptosisGeneticsInflammationImmunologyASCCaspase-8caspase-1Zbp1Ripk1Ripk3PanoptosisPanoptosome

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 8 of CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial–mesenchymal transition, G2/M phase transition, and PANoptosis

10.6084/m9.figshare.21261638.v1figshare

Additional file 8 of CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial–mesenchymal transition, G2/M phase transition, and PANoptosis

10.6084/m9.figshare.21261638figshare

Additional file 1 of Inhibition of GSK3β activity alleviates acute liver failure via suppressing multiple programmed cell death

10.6084/m9.figshare.23682271.v1figshare

Additional file 1 of Inhibition of GSK3β activity alleviates acute liver failure via suppressing multiple programmed cell death

10.6084/m9.figshare.23682271figshare

Additional file 6 of CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial–mesenchymal transition, G2/M phase transition, and PANoptosis

10.6084/m9.figshare.21261632.v1figshare

Additional file 5 of CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial–mesenchymal transition, G2/M phase transition, and PANoptosis

10.6084/m9.figshare.21261629.v1figshare

Additional file 4 of CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial–mesenchymal transition, G2/M phase transition, and PANoptosis

10.6084/m9.figshare.21261626figshare

Additional file 7 of CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial–mesenchymal transition, G2/M phase transition, and PANoptosis

10.6084/m9.figshare.21261635.v1figshare

Additional file 5 of CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial–mesenchymal transition, G2/M phase transition, and PANoptosis

10.6084/m9.figshare.21261629figshare

Additional file 2 of CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial–mesenchymal transition, G2/M phase transition, and PANoptosis

10.6084/m9.figshare.21261620figshare

Additional file 1 of CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial–mesenchymal transition, G2/M phase transition, and PANoptosis

10.6084/m9.figshare.21261617.v1figshare

Additional file 7 of CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial–mesenchymal transition, G2/M phase transition, and PANoptosis

10.6084/m9.figshare.21261635figshare

Additional file 1 of CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial–mesenchymal transition, G2/M phase transition, and PANoptosis

10.6084/m9.figshare.21261617figshare

Additional file 4 of CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial–mesenchymal transition, G2/M phase transition, and PANoptosis

10.6084/m9.figshare.21261626.v1figshare

Additional file 6 of CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial–mesenchymal transition, G2/M phase transition, and PANoptosis

10.6084/m9.figshare.21261632figshare

Additional file 3 of CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial–mesenchymal transition, G2/M phase transition, and PANoptosis

10.6084/m9.figshare.21261623.v1figshare

Additional file 2 of CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial–mesenchymal transition, G2/M phase transition, and PANoptosis

10.6084/m9.figshare.21261620.v1figshare

Additional file 3 of CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial–mesenchymal transition, G2/M phase transition, and PANoptosis

10.6084/m9.figshare.21261623figshare